Holen Sie sich die Stockscreener-App
18.00
0.62%
0.27
Schlusskurs vom Vortag:
$17.73
Offen:
$17.8
24-Stunden-Volumen:
109.42K
Relative Volume:
0.27
Marktkapitalisierung:
$6.43B
Einnahmen:
$5.21B
Nettoeinkommen (Verlust:
$-211.00M
KGV:
-29.13
EPS:
-0.6179
Netto-Cashflow:
$861.30K
1W Leistung:
-0.89%
1M Leistung:
+6.32%
6M Leistung:
+3.60%
1J Leistung:
+16.60%
1-Tages-Spanne:
$17.79
$18.20
1-Wochen-Bereich:
$17.47
$18.27
52-Wochen-Spanne:
$13.77
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
18.01 | 6.33B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
350.73 | 123.70B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.99 | 48.78B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
68.91 | 33.41B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
219.90 | 31.89B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
34.77 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Neutral |
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
(BLCO) Advanced Trading Insights (BLCO:CA) - Stock Traders Daily
Bausch + Lomb Corporation (BLCO) Investor Outlook: Eyeing a 3.24% Upside Amid Diverse Global Operations - DirectorsTalk Interviews
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
Bausch + Lomb stock rises on survey-driven dry eye focus - AD HOC NEWS
Why Bausch + Lomb Corp stock is gaining today - Wealth Awesome
Bausch + Lomb study shows enVista Aspire lenses improve vision By Investing.com - Investing.com Canada
Bausch + Lomb study shows enVista Aspire lenses improve vision - Investing.com
Every patient in the study reached mid-range vision after cataract surgery. - Stock Titan
Does Advancing First-in-Class Dry Eye and Pain Drugs Change The Bull Case For Bausch + Lomb (BLCO)? - simplywall.st
Is Bausch + Lomb (TSX:BLCO) Strengthening Eye Care Leadership? - Kalkine Media
Bausch + Lomb Corporation - Menafn
Bausch + Lomb Survey Finds 14% Link Dry Eye to Menopause | BLCO Stock News - Stock Titan
Bausch + Lomb Corporation (BLCO) Stock Report: Analyzing a 9.10% Revenue Growth in the Healthcare Sector - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers - Yahoo Finance
H.C. Wainwright reiterates Bausch & Lomb stock rating on pipeline data - Investing.com
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack - Yahoo Finance
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal - TradingView
Bausch + Lomb eye drop cut pain duration from 37.8 seconds to 1.6 - Stock Titan
Trading (BLCO) With Integrated Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine - Seeking Alpha
Did Bausch + Lomb’s (BLCO) Board Overhaul Amid Weak Returns Just Shift Its Investment Narrative? - simplywall.st
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing a 9.24% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Director Robert J. Chersi Granted 11,776 RSUs Under 2022 Incentive Plan - Kalkine Media
Bausch & Lomb (BLCO) director Barbara Trebbi receives 11,776-share RSU award - Stock Titan
Bausch & Lomb (BLCO) files Form 3 for new director Barbara Trebbi - Stock Titan
Bausch & Lomb (BLCO) director awarded 11,776 RSU-based common shares - Stock Titan
Bausch & Lomb (BLCO) director receives 11,776 RSU equity grant as compensation - Stock Titan
Bausch & Lomb Corp (BLCO) adds director Robert J. Chersi in Form 3 filing - Stock Titan
Bausch & Lomb Corp (BLCO) director Thomas Appio reports holding 27,583 shares - Stock Titan
Why Could Bausch + Lomb (TSX:BLCO) Gain From Aging Demographics? - Kalkine Media
Senior VP Of Bausch + Lomb Sold 54% Of Their Shares - Moomoo
Bausch + Lomb (NYSE:BLCO) CAO Sells 52,900 Shares - marketbeat.com
Bausch & Lomb (BLCO) SVP Frederick Munsch sells 52,900 shares in August trade - Stock Titan
Is Bausch + Lomb’s Raised 2026 Outlook And Board Refresh Altering The Investment Case For BLCO? - simplywall.st
Form 8K Bausch & Lomb Corp For: 12 August By Investing.com - Investing.com South Africa
Bausch & Lomb Corp (BLCO) Director Andrew C. von Eschenbach Sells 18,559 Shares - GuruFocus
BLCO (BLCO) shareholder plans NYSE sale of 52,900 restricted shares - Stock Titan
Bausch + Lomb (NYSE:BLCO) Director Eschenbach Andrew Von Sells 12,500 Shares - MarketBeat
Bausch & Lomb (NYSE: BLCO) director sells 18,559 shares after board exit - Stock Titan
Insider Selling: Bausch + Lomb (NYSE:BLCO) Director Sells $100,458.22 in Stock - MarketBeat
BLCO | Bausch + Lomb Corporation FinancialsIncome Statement - Quiver Quantitative
BLCO shareholder plans $887,885 stock sale (NYSE: BLCO) - Stock Titan
Bausch + Lomb Corporation (BLCO): Growth Potential and Analyst Ratings Point to an 11% Upside - DirectorsTalk Interviews
Bausch + Lomb Updates Board, Reaffirms 2026 Guidance - VisionMonday.com
Bausch + Lomb Corporation $BLCO Shares Bought by Sei Investments Co. - marketbeat.com
Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Bausch Lomb (BLCO) investor plans sale of 12,500 common shares - Stock Titan
Bausch & Lomb Corp (BLCO) awards 16,778 performance-based shares to executive - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP earns PSUs for 9,091 shares - Stock Titan
Bausch & Lomb Corp (BLCO) EVP awarded 20,973 PSUs after targets met - stocktitan.net
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):